Clinical trial
Treatment of Autoimmune Thrombocytopenia (AITP)
NCT00001630 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00001630 |
|---|---|
| Title | Treatment of Autoimmune Thrombocytopenia (AITP) |
| Official title | High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Autoimmune Disease, Autoimmune Hemolytic Anemia, Thrombocytopenia |
| Intervention type | Device |
| Interventions | Isolex 300i |
| Enrollment | 29 |
| Start date | Jul 21, 1997 |
| Completion | Jun 11, 2009 |
| First posted | Nov 4, 1999 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: